Results 11 to 20 of about 5,352 (210)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS [PDF]

HIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj   +3 more sources

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study. [PDF]

PLoS ONE, 2022
BackgroundCoronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in ...
Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal   +10 more
doaj   +2 more sources

Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient

Virology Journal, 2023
Background Solid-organ transplantation due to end-stage organ disease is increasingly performed in people living with HIV. Despite improved transplant outcomes, management of these patients remains challenging due to higher risk for allograft rejection ...
Andrea Erba, Catia Marzolini, Katharina Rentsch, Marcel Stoeckle, Manuel Battegay, Michael Mayr, Maja Weisser   +6 more
doaj   +2 more sources

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS: Research and Palliative Care, 2015
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of ...
von Hentig N
doaj   +1 more source

Iatrogenic Cushing’s Syndrome: The Result of Cobicistat and Glucocorticoid Interaction in an HIV Patient After Bariatric Surgery [PDF]

, 2023
Cobicistat, used as a pharmacokinetic booster in therapeutic combination with human immunodeficiency virus (HIV) protease inhibitors and integrase inhibitors, is a strong inhibitor of cytochrome P450 3A4 (CYP3A4).
Esteves Brandão, Maria, Benido Silva, Vânia, Mesquita, Isabel, Pereira, Maria Teresa, Cardoso, Joana   +4 more
core   +1 more source

Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece. [PDF]

HIV Med
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Leonidou L, Lourida G, Protopapas K, Moschopoulos CD, Zoulas D, Totsikas C, Basoulis D, Mastrogianni E, Beloukas A, Lagadinou M, Marangos M, Papastamopoulos V, Papadopoulos A, Psichogiou M.   +13 more
europepmc   +2 more sources

Considerations for the Use of AAV-based Gene Therapy in HIV-Positive Individuals With Haemophilia. [PDF]

Haemophilia
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Rockstroh JK, Stingl JC, Stadler M, Reichert A, Wedemeyer H, Oldenburg J.   +5 more
europepmc   +2 more sources

Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib. [PDF]

Clin Pharmacokinet
Objectives: Pharmacokinetic (PK) boosting is the intentional use of strong inhibitors of metabolic enzymes or transporters to boost the systemic exposure of a therapeutic drug.
Overbeek JK, van Erp NP, Burger DM, den Broeder AA, Koolen SLW, Huitema ADR, Ter Heine R.   +6 more
europepmc   +4 more sources

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Clinical and Translational Science, 2021
The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK‐positive non‐small cell lung cancer (NSCLC).
Nicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, Gerd Mikus, Antje Blank, Jürgen Burhenne, Michael Thomas, Walter E. Haefeli   +7 more
doaj   +1 more source

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

Future Journal of Pharmaceutical Sciences, 2022
Background The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography. Result The separation
Challamalla Pavani, E. Susithra
doaj   +1 more source